metadata toggle
Contra-indications, warnings, etc
Do not use in pregnant animals, for which induction of abortion or parturition is not intended. Do not use in animals with spastic diseases of the respiratory or gastrointestinal tract.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Adverse Reactions
Cattle (cows):
Very rare
(<1 animal / 10,000 animals treated, including isolated reports):
Anaphylactic-type reaction *
Undetermined frequency (cannot be estimated from the available data):
Injection site infection **
Retained placenta ***
* Anaphylactic-type reactions can be observed which might be life threatening and require rapid medical care.
** Anaerobic infection if anaerobic bacteria penetrate the tissue at injection site, in particular following intramuscular injection.
*** When used for induction of parturition and dependent on the time of treatment relative to the date of conception, the incidence of retained placenta may be increased.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.
Interaction with other medicines
Concurrent use of oxytocin and cloprostenol increases effects on the uterus. The activity of other oxytocic agents can be increased after the administration of cloprostenol.
Do not use in animals being treated with non-steroidal anti-inflammatories, as the synthesis of endogenous prostaglandins is inhibited.
Overdose
Therapeutic tolerance in cattle is broad. Overdoses of more than 10 times are generally well tolerated. Large overdoses may cause transient diarrhoea. No antidotes are available.
An overdose will not accelerate corpus luteum regression.
Withdrawal periods
Meat and offal: 2 days
Milk: Zero hours